In people with vision loss from DME, treatment with intravitreal RG7716 resulted in clinically meaningful and statistically significant improvements in visual acuity gains compared with ranibizumab alone.
Key secondary and exploratory anatomical outcomes, reduction of central retina thickness and improvements in diabetic retinopathy severity scores, were supportive of the primary outcome.
RG7716 is the first known bispecific, monoclonal antibody specifically designed for the eye that simultaneously binds to and inactivates vascular endothelial growth factor A (VEGF-A) and Angiopoietin-2 (Ang-2). In DME, Ang-2 works synergistically with VEGF to drive biological pathways that cause vessel permeability and inflammation; both contribute to vascular instability which results in vision loss.
BOULEVARD assessed two doses of RG7716 (1.5 mg and 6 mg) versus ranibizumab standard of care (0.3 mg) given as monthly intravitreal injections.
Genentech is researching and developing new treatments for people living with a range of eye diseases that cause significant visual impairment and blindness, including neovascular age-related macular degeneration, diabetic macular edema, diabetic retinopathy, geographic atrophy and other retinal diseases. Genentech is also investigating platforms for sustained ocular drug delivery.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007